Kymera Therapeutics (KYMR) Assets Average (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Assets Average data on file, last reported at $1.7 billion in Q1 2026.

• On a quarterly basis, Assets Average rose 79.92% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 79.92% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 75.11% from the prior year.
• Assets Average for Q1 2026 stood at $1.7 billion, up from $1.4 billion in the prior quarter.
• Over the last five years, Assets Average for KYMR reached as high as $1.7 billion in Q1 2026 and fell as low as $543.2 million in Q2 2022.
• Historically, Assets Average has averaged $846.5 million across 5 years, with a median of $722.0 million in 2024.
• Across the five-year window, Assets Average slipped 9.14% in 2023 and surged 79.92% in 2026, its largest moves.
• Year by year, Assets Average stood at $620.8 million in 2022, then dropped by 9.14% to $564.1 million in 2023, then surged by 78.42% to $1.0 billion in 2024, then surged by 41.33% to $1.4 billion in 2025, then advanced by 19.93% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.7 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.1 billion in Q3 2025.